MYC and neoplasm: Systemic CBD-IL-12 administration induced significant tumor growth inhibition in both syngeneic RM9 and Myc-CaP tumor models which were otherwise poorly responsive to anti-PD-1 therapy (Fig. 6b, Supplementary Fig. 16a).